Eylea’s Global Net Sales Increase 20 Percent in Q1-2018

May 4, 2018: By Jon Swedien

Net sales for Eylea (aflibercept) across the globe rose to $1.61 billion in Q1-2018, up 20 percent compared with Q1-2017, Regeneron reported May 3.

Eylea’s net sales in the US in Q1-2018 were $984 million, a 15 percent increase compared with the same quarter from the prior year, Regeneron reported.

Bayer commercializes Eylea outside the US, where the anti-VEGF’s net sales for Q1-2018 were $624 million, a 29 percent increase compared with Q1-2017, Regeneron said.

Regeneron recognized nearly $248 million in Q1-2018 from its share of net profit from Eylea sales outside the US, the company said.

Eylea gained approval in March from China’s FDA for the treatment of visual impairment due to diabetic macular edema (DME).

In addition, Eylea in March met its 24-week primary endpoint in a Phase III trial evaluating the anti-VEGF as a treatment for moderately severe to severe nonproliferative diabetic retinopathy.

Regeneron’s total revenues for the quarter were $1.5 billion, a 15 percent increase compared with Q1-2017, the Tarrytown, New York, company reported.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility